FDA approves FoundationOneCDx to identify NTRK gene fusion in patients eligible for Vitrakvi
FoundationOneCDx analyses substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in NTRK gene fusions
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Oct 20
FoundationOneCDx analyses substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in NTRK gene fusions
23 Oct 20
Thermo Fisher logged the highest quarterly increase of 2020 in its Q3 financial statement, with sales related to…
23 Oct 20
The transaction is expected to strengthen Eurofins Transplant Diagnostics position in the pre- and post-transplantation organ testing market
23 Oct 20
A behind-the-scenes look at how DnaNudge went from promoting healthcare outside of hospitals to testing for Covid-19 in…
23 Oct 20
Last year, the company secured CE Marking to market the assay in the European Union and other CE…
23 Oct 20
Effective November 1, 2020, this new three-year agreement in the video endoscope category allows Premier members to access…
23 Oct 20
Developed with key partners, Hamilton Company, Thermo Fisher, Grenova, and Premier Medical Laboratory Services
23 Oct 20
The companies will market the FDA, EUA authorized, Assure/FaStep Point-of-Care Covid-19 antibody tests
22 Oct 20
The CE mark enables the use of the VIASURE SARS-CoV-2 (N1 + N2) real-time PCR detection kit on…
22 Oct 20
The MR systems will provide software and services to enhance diagnoses spanning from brain injuries, liver and cardiac…